Estech, a small cardiac surgery and surgical ablation company, figured it had its strategy all set: after taking an investment from Boston Scientific, it would ramp up commercialization and, once it hit a certain sales target, would be acquired by BSC. But when Boston itself changed its strategy around the small companies in which it had made investments, Estech found itself in trouble.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
